Making decisions in the absence of high quality clinical evidence: we need to bring some science into the judgement.
Anderson
Ian
I
Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK. ian.anderson@manchester.ac.uk
D000081:Acetamides / Q000191:economics / Q000627:therapeutic use*; D053961:Azabicyclo Compounds; D001569:Benzodiazepines / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D006801:Humans; D006993:Hypnotics and Sedatives / Q000191:economics / Q000627:therapeutic use*; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use*; D011725:Pyridines / Q000191:economics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000191:economics*; D000077334:Zolpidem
D000081:Acetamides; D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; D011725:Pyridines; D011743:Pyrimidines; C515050:zopiclone; D001569:Benzodiazepines; D000077334:Zolpidem; C085665:zaleplon